Acute bacterial skin and skin structure infections (ABSSSI) Contraindicated for patients with hypersensitivity to Tedizolid and ingredients

Other antibiotic

After conversion to its active form by phosphatases, tedizolid exerts its antibacterial activity through inhibition of protein synthesis by binding to the 50S ribosomal subunit of susceptible Gram-positive bacteria. Cross-resistance between other non-oxazolidinone antibacterial drugs is unlikely as it inhibits bacterial protein synthesis through a different mechanism.

Administration: Oral Administration May take with or without food IV Administration Administer as IV infusion over 1 hr Do NOT give as IV push or bolus Not for intra-arterial, IM, IT, intraperitoneal, or SC administration Adult Dose: Adult: 200 mg PO/IV once daily for 6 days Hepatic impairment: No dosage adjustment required Child Dose: <18 years: Safety and efficacy not established Renal Dose: Renal impairment or hemodialysis: No dosage adjustment required

Increased AUC & Cmax of rosuvastatin. Inhibition of BCRP at the intestinal level, increased plasma conc of BCRP substrates, & the potential for adverse reactions especially for BCRP substrates w/ narrow therapeutic index (eg, methotrexate or topotecan), or rosuvastatin.

Contraindicated for patients with hypersensitivity to Tedizolid and ingredients

2-10% Nausea (8%) Headache (6%) Diarrhea (4%) Hemoglobin <10.1 g/dL (3.1%) Vomiting (3%) Platelets <112 x 10³/mm³ (2.3%) Dizziness (2%) <2% Blood and lymphatic system disorders: Anemia Cardiovascular: Palpitations, tachycardia Eye disorders: Asthenopia, vision blurred, visual impairment, vitreous floaters General disorders and administration site conditions: Infusion-related reactions Immune system disorders: Drug hypersensitivity Infections and infestations: Clostridium difficile colitis, oral candidiasis, vulvovaginal mycotic infection Investigations: Hepatic transaminases increased, decreased WBCs Nervous system disorders: Hypoesthesia, paresthesia, seventh nerve paralysis Psychiatric disorders: Insomnia Skin and subcutaneous tissue disorders: Pruritus, urticaria, dermatitis Vascular disorders: Flushing, hypertension

Pregnancy category C. There are no adequate and well-controlled studies of Tedizolid in pregnant women. Tedizolid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Nursing Mothers: Tedizolid is excreted in the breast milk of rats. It is not known whether tedizolid is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Tedizolid is administered to a nursing woman.

Precaution: Patients w/ neutropenia (neutrophil counts <1,000 cells/mm3). Discontinue if C. difficile-associated diarrhoea (CDAD) is suspected or confirmed. Patients w/ concomitant complicated skin & soft tissue infection & secondary bacteremia & in treatment of ABSSSI w/ severe sepsis or septic shock; diabetic foot infections, decubitus or ischaemic ulcers, bone or joint infections, severe burns, necrotizing infections or gangrene. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr. Elderly ≥75 yr.

In the event of overdosage, Tedizolid should be discontinued and general supportive treatment given. Hemodialysis does not result in meaningful removal of tedizolid from systemic circulation

Tablets and injection should be stored at 20°C to 25°C

Other antibiotic

Inhibits protein synthesis by binding with 50S ribosomal sub-unit in bacteria

Pregnancy category C. There are no adequate and well-controlled studies of Tedizolid in pregnant women. Tedizolid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Nursing Mothers: Tedizolid is excreted in the breast milk of rats. It is not known whether tedizolid is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Tedizolid is administered to a nursing woman.